Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections (CROI) February 13-16, 2017, Seattle WA Back

Oral Session Thursday: INFLAMMATION AND AGE-RELATED COMPLICATIONS       from Jules: Here are reports from this oral session on Thursday along with links to webcasts on (1) "Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors [darunavir & Reyataz] - D:A:D", (2) smoking cessation [D:A:D] and impact on cancers where they followed HIV+ subjects for 5 years and found that smoking cessation in HIV reduced overall cancers risks but not lung cancers after 5 years but there was a slight reduction in year 5 for lung cancer so authors suggest we need longer followup and perhaps with more time lung cancer rates will decline, (3) billirubin & its affect on CVD where they found higher billirubin levels can reduce CVD, (4) promising study results - study of an anti-inflammatory called Canakinumab on CVD risks, a monoclonal antibody used in other diseases, studied here in a small pilot study in HIV+ where they found of note this drug did reduce inflammation markers quite a lot and will start large followup study.   -------------------------------   CROI 2017, Seattle,   Late Breaker Presentation Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors   L Ryom, JD Lundgren, W El-Sadr, P Reiss, A Phillips, O Kirk, R Weber, E Fontas, AD Monforte, S de Wit, F Dabis, CI Hatleberg, C Sabin, A Mocroft On behalf of the D:A:D Study group see full slide report following links just below to other studies covered in this report.   ---------------------------------   Related Press Conference Webcast to hear study authors summaries: http://www.croiwebcasts.org/console/player/33607?mediaType=slideVideo&   HYPERBILIRUBINEMIA PREVENTS CARDIOVASCULAR DISEASE FOR HIV+ AND HIV- INDIVIDUALS   Vincent C. Marconi School of Medicine, Emory University, Atlanta, GA, USA http://www.croiwebcasts.org/console/player/33598?mediaType=slideVideo&   ------------------   IL-1β INHIBITION SIGNIFICANTLY REDUCES ATHEROSCLEROTIC INFLAMMATION IN TREATED HIV   Priscilla Hsue University of California, San Francisco, San Francisco, CA, USA http://www.croiwebcasts.org/console/player/33597?mediaType=slideVideo&   this was a pilot study in only 10 HIV+ subjects. Patient study subjects were HIV+, 59 years old and 24 years HIV duration, with elevated lipids on a statin. Patients received a single subcutaneous injection in insulin syringe in this pilot study. In the followup randomized controlled study in 100 patients will receive 2 doses at baseline and week 12 and will be followed for 36 weeks to much better evaluate this therapy.   Hsue concluded "this is the first we believe this is one of the first immune based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV, one of the first to show improved arterial inflammation & bone marrow activity." -------------------------   CESSATION OF CIGARETTE SMOKING AND THE IMPACT ON CANCER INCIDENCE IN THE D:A:D STUDY   Leah Shepherd University College London, London, United Kingdom http://www.croiwebcasts.org/console/player/33602?mediaType=slideVideo&   -------------------------   Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors   L Ryom, JD Lundgren, W El-Sadr, P Reiss, A Phillips, O Kirk, R Weber, E Fontas, AD Monforte, S de Wit, F Dabis, CI Hatleberg, C Sabin, A Mocroft On behalf of the D:A:D Study group   Webcast: http://www.croiwebcasts.org/console/player/33599?mediaType=slideVideo&